Business Description
Joinn Laboratories (China) Co Ltd
ISIN : CNE100002W27
Share Class Description:
SHSE:603127: Class ACompare
Compare
Traded in other countries / regions
603127.China06127.Hong Kong IPO Date
2017-08-25Description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 52.09 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 27.07 | |||||
Interest Coverage | 192.88 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.47 | |||||
Beneish M-Score | -2.86 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.5 | |||||
3-Year EBITDA Growth Rate | 8 | |||||
3-Year EPS without NRI Growth Rate | -1.2 | |||||
3-Year FCF Growth Rate | 8.6 | |||||
3-Year Book Growth Rate | 78 | |||||
Future 3-5Y EPS without NRI Growth Rate | 26.54 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.1 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.87 | |||||
9-Day RSI | 51.94 | |||||
14-Day RSI | 49.57 | |||||
6-1 Month Momentum % | -23.82 | |||||
12-1 Month Momentum % | -49.45 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.64 | |||||
Quick Ratio | 3.51 | |||||
Cash Ratio | 2.2 | |||||
Days Inventory | 530.69 | |||||
Days Sales Outstanding | 27.71 | |||||
Days Payable | 13.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.87 | |||||
Dividend Payout Ratio | 1.9 | |||||
3-Year Dividend Growth Rate | 65 | |||||
Forward Dividend Yield % | 1.15 | |||||
5-Year Yield-on-Cost % | 30.09 | |||||
3-Year Average Share Buyback Ratio | -6.3 | |||||
Shareholder Yield % | 3.11 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 39.82 | |||||
Operating Margin % | 23.62 | |||||
Net Margin % | -2.7 | |||||
FCF Margin % | 24.04 | |||||
ROE % | -0.77 | |||||
ROA % | -0.62 | |||||
ROIC % | 1142.18 | |||||
ROC (Joel Greenblatt) % | 0.09 | |||||
ROCE % | 0.03 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 31.15 | |||||
PE Ratio without NRI | 66.29 | |||||
Shiller PE Ratio | 32.5 | |||||
PEG Ratio | 1.82 | |||||
PS Ratio | 4.04 | |||||
PB Ratio | 1.31 | |||||
Price-to-Tangible-Book | 1.38 | |||||
Price-to-Free-Cash-Flow | 16.19 | |||||
Price-to-Operating-Cash-Flow | 12.14 | |||||
EV-to-EBIT | 2692.99 | |||||
EV-to-Forward-EBIT | 13.91 | |||||
EV-to-EBITDA | 2692.99 | |||||
EV-to-Revenue | 2.71 | |||||
EV-to-Forward-Revenue | 2.7 | |||||
EV-to-FCF | 11.25 | |||||
Price-to-Projected-FCF | 0.95 | |||||
Price-to-DCF (Earnings Based) | 2.13 | |||||
Price-to-DCF (FCF Based) | 0.52 | |||||
Price-to-Graham-Number | 2.02 | |||||
Price-to-Net-Current-Asset-Value | 2 | |||||
Price-to-Net-Cash | 6.68 | |||||
Earnings Yield (Greenblatt) % | 0.04 | |||||
FCF Yield % | 5.89 | |||||
Forward Rate of Return (Yacktman) % | 23.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Joinn Laboratories (China) Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 2,331.909 | ||
EPS (TTM) (Â¥) | -0.09 | ||
Beta | 1.35 | ||
Volatility % | 39.28 | ||
14-Day RSI | 49.57 | ||
14-Day ATR (Â¥) | 0.539926 | ||
20-Day SMA (Â¥) | 13.6345 | ||
12-1 Month Momentum % | -49.45 | ||
52-Week Range (Â¥) | 12.32 - 29.67 | ||
Shares Outstanding (Mil) | 749.48 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Joinn Laboratories (China) Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Joinn Laboratories (China) Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Joinn Laboratories (China) Co Ltd Frequently Asked Questions
What is Joinn Laboratories (China) Co Ltd(SHSE:603127)'s stock price today?
The current price of SHSE:603127 is ¥13.97. The 52 week high of SHSE:603127 is ¥29.67 and 52 week low is ¥12.32.
When is next earnings date of Joinn Laboratories (China) Co Ltd(SHSE:603127)?
The next earnings date of Joinn Laboratories (China) Co Ltd(SHSE:603127) is .
Does Joinn Laboratories (China) Co Ltd(SHSE:603127) pay dividends? If so, how much?
The Dividend Yield %  of Joinn Laboratories (China) Co Ltd(SHSE:603127) is 2.87% (As of Today), Highest Dividend Payout Ratio of Joinn Laboratories (China) Co Ltd(SHSE:603127) was 1.9. The lowest was 0.18. And the median was 0.21. The  Forward Dividend Yield % of Joinn Laboratories (China) Co Ltd(SHSE:603127) is 1.15%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |